| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Actigraphic and patient and family reported sleep outcomes in children and youth with cystic fibrosis: A systematic review
|
McMurray, Jordana
|
|
|
21 |
2 |
p. e49-e82
|
article
|
| 2 |
Administration and monitoring of clofazimine for NTM infections in children with and without cystic fibrosis
|
Cameron, LH
|
|
|
21 |
2 |
p. 348-352
|
article
|
| 3 |
Advanced but not mild liver disease is a predictor of decreased survival in children with cystic fibrosis, with far greater impact in females: A 27-year real-life cohort study
|
Baldissera, Marilisa
|
|
|
21 |
2 |
p. 230-235
|
article
|
| 4 |
A new path for CF clinical trials through the use of historical controls
|
Magaret, Amalia S.
|
|
|
21 |
2 |
p. 293-299
|
article
|
| 5 |
A new perspective on opportunistic pathogens of the genus Bordetella in cystic fibrosis
|
Menetrey, Quentin
|
|
|
21 |
2 |
p. 344-347
|
article
|
| 6 |
Aquagenic wrinkling of the palms in cystic fibrosis patients treated with ivacaftor
|
Jacobi, Eyal
|
|
|
21 |
2 |
p. e102-e105
|
article
|
| 7 |
Arm muscle area for the longitudinal assessment of nutritional status in paediatric patients with cystic fibrosis - A single centre experience
|
Ellemunter, Helmut
|
|
|
21 |
2 |
p. e122-e128
|
article
|
| 8 |
A year in review: Real world evidence, functional monitoring and emerging therapeutics in 2021
|
Barr, H.L.
|
|
|
21 |
2 |
p. 191-196
|
article
|
| 9 |
Barriers implementing infection prevention and control experienced by healthcare workers, people with CF and parents
|
Saiman, Lisa
|
|
|
21 |
2 |
p. 309-315
|
article
|
| 10 |
Clinical presentation and basic defect of the CFTR genotype p.Phe508del / p.Arg117His in a mother and her monozygous twin daughters
|
Lex, Christiane
|
|
|
21 |
2 |
p. 375-377
|
article
|
| 11 |
Defining and Treating Cystic Fibrosis Liver Disease: Some Things Old and Some Things New
|
Galante, Gary J.
|
|
|
21 |
2 |
p. 199-201
|
article
|
| 12 |
Drug-induced liver injury from elexacaftor/ivacaftor/tezacaftor
|
Lowry, Sarah
|
|
|
21 |
2 |
p. e99-e101
|
article
|
| 13 |
Editorial Board
|
|
|
|
21 |
2 |
p. ii
|
article
|
| 14 |
Effect of elexacaftor-tezacaftor-ivacaftor on body weight and metabolic parameters in adults with cystic fibrosis
|
Petersen, Max C.
|
|
|
21 |
2 |
p. 265-271
|
article
|
| 15 |
Exercise intolerance in cystic fibrosis-the role of CFTR modulator therapies
|
Caterini, Jessica E.
|
|
|
21 |
2 |
p. 282-292
|
article
|
| 16 |
Forskolin induced swelling (FIS) assay in intestinal organoids to guide eligibility for compassionate use treatment in a CF patient with a rare genotype
|
Aalbers, B.L.
|
|
|
21 |
2 |
p. 254-257
|
article
|
| 17 |
From the Editor's Desk
|
Flume, Patrick A.
|
|
|
21 |
2 |
p. 197-198
|
article
|
| 18 |
Functional Restoration of CFTR Nonsense Mutations in Intestinal Organoids
|
de Poel, E.
|
|
|
21 |
2 |
p. 246-253
|
article
|
| 19 |
Gamma-glutamyl transpeptidase-to-platelet ratio as a biomarker of liver disease and hepatic fibrosis severity in paediatric Cystic Fibrosis
|
Calvopina, Diego A.
|
|
|
21 |
2 |
p. 236-242
|
article
|
| 20 |
Incidence and risk factors of cancer in individuals with cystic fibrosis in the UK; a case-control study
|
Archangelidi, Olga
|
|
|
21 |
2 |
p. 302-308
|
article
|
| 21 |
Indoor air pollution exposure is associated with greater morbidity in cystic fibrosis
|
Carson, Sara W.
|
|
|
21 |
2 |
p. e129-e135
|
article
|
| 22 |
Lumacaftor-ivacaftor effects on cystic fibrosis-related liver involvement in adolescents with homozygous F508 del-CFTR
|
Drummond, David
|
|
|
21 |
2 |
p. 212-219
|
article
|
| 23 |
Macrophages from gut-corrected CF mice express human CFTR and lack a pro-inflammatory phenotype
|
Gillan, Jonathan L
|
|
|
21 |
2 |
p. 370-374
|
article
|
| 24 |
Magnetic resonance imaging of cystic fibrosis: Multi-organ imaging in the age of CFTR modulator therapies
|
McBennett, Kimberly
|
|
|
21 |
2 |
p. e148-e157
|
article
|
| 25 |
Management of Cystic Fibrosis during COVID-19: Patient Reported Outcomes based remote follow-up among CF patients in Denmark – A feasibility study
|
Rodkjær, Lotte
|
|
|
21 |
2 |
p. e106-e112
|
article
|
| 26 |
Mental status changes during elexacaftor/tezacaftor / ivacaftor therapy
|
Heo, Suyeon
|
|
|
21 |
2 |
p. 339-343
|
article
|
| 27 |
News article
|
|
|
|
21 |
2 |
p. 189-190
|
article
|
| 28 |
Olfactory dysfunction in cystic fibrosis: Impact of CFTR modulator therapy
|
Beswick, Daniel M.
|
|
|
21 |
2 |
p. e141-e147
|
article
|
| 29 |
Pilot RCT of a telehealth intervention to reduce symptoms of depression and anxiety in adults with cystic fibrosis
|
Bathgate, Christina J.
|
|
|
21 |
2 |
p. 332-338
|
article
|
| 30 |
Response to elexacaftor/tezacaftor/ivacaftor in intestinal organoids derived from people with cystic fibrosis
|
Furstova, Eva
|
|
|
21 |
2 |
p. 243-245
|
article
|
| 31 |
Restoration of exocrine pancreatic function in child with lumacaftor/ivacaftor therapy in cystic fibrosis
|
Crowley, J.
|
|
|
21 |
2 |
p. 264
|
article
|
| 32 |
Rethinking physical exercise training in the modern era of cystic fibrosis: A step towards optimising short-term efficacy and long-term engagement
|
Gruet, Mathieu
|
|
|
21 |
2 |
p. e83-e98
|
article
|
| 33 |
SARS-CoV-2 antibodies among people with cystic fibrosis prior to the vaccination campaign: A seroprevalence study in two specialized centres in Northern Italy
|
Alicandro, Gianfranco
|
|
|
21 |
2 |
p. e113-e116
|
article
|
| 34 |
Serological biomarkers for the diagnosis of Mycobacterium abscessus infections in cystic fibrosis patients
|
Le Moigne, Vincent
|
|
|
21 |
2 |
p. 353-360
|
article
|
| 35 |
Structural lung disease in preschool children with cystic fibrosis: An 18 month natural history study
|
Brody, Alan S.
|
|
|
21 |
2 |
p. e165-e171
|
article
|
| 36 |
The effectiveness of exercise interventions to increase physical activity in Cystic Fibrosis: A systematic review
|
Curran, M.
|
|
|
21 |
2 |
p. 272-281
|
article
|
| 37 |
The effect of elexacaftor/tezacaftor/ivacaftor (ETI) on glycemia in adults with cystic fibrosis
|
Scully, Kevin J.
|
|
|
21 |
2 |
p. 258-263
|
article
|
| 38 |
The impact of cystic fibrosis on the working life of patients: A systematic review
|
Leso, Veruscka
|
|
|
21 |
2 |
p. 361-369
|
article
|
| 39 |
The impact of liver disease on mortality in cystic fibrosis–A systematic review
|
Sasame, Ao
|
|
|
21 |
2 |
p. 202-211
|
article
|
| 40 |
TLR5 signalling is hyper-responsive in porcine cystic fibrosis airways epithelium
|
Fleurot, Isabelle
|
|
|
21 |
2 |
p. e117-e121
|
article
|
| 41 |
Treatment patterns in people with cystic fibrosis: have they changed since the introduction of ivacaftor?
|
Granger, Emily
|
|
|
21 |
2 |
p. 316-322
|
article
|
| 42 |
Unexpected associations between respiratory viruses and bacteria with Pulmonary Function Testing in children suffering from Cystic Fibrosis (MUCOVIB study)
|
Scherz, Valentin
|
|
|
21 |
2 |
p. e158-e164
|
article
|
| 43 |
Urinary sodium/creatinine ratio is a predictor for fractional sodium excretion and related to age in patients with cystic fibrosis
|
Declercq, Dimitri
|
|
|
21 |
2 |
p. e136-e140
|
article
|
| 44 |
Ursodeoxycholic acid and liver disease associated with cystic fibrosis: A multicenter cohort study
|
Colombo, Carla
|
|
|
21 |
2 |
p. 220-226
|
article
|
| 45 |
Use of elexacaftor/tezacaftor/ivacaftor in liver transplant patients with cystic fibrosis
|
McKinzie, Cameron J.
|
|
|
21 |
2 |
p. 227-229
|
article
|
| 46 |
Using a learning health system to understand the mismatch between medicines supply and actual medicines use among adults with cystic fibrosis
|
Bevan, Amanda
|
|
|
21 |
2 |
p. 323-331
|
article
|
| 47 |
Working in partnership with the patient community to develop outline trial designs in CF
|
Rowbotham, NJ
|
|
|
21 |
2 |
p. 300-301
|
article
|
Journal description